多病共存测量中的高阶疾病交互作用:相较加性求和边际获益有限
该研究基于健康与退休研究(HRS)1991—2012年关联Medicare的ICD-9-CM索赔数据,将高阶疾病交互作用纳入已验证的多病加权指数,评估模型改善程度。结果显示,纳入前10位最常见且影响最大疾病的二向交互作用仅使R²由0.26升至0.27,三向交互作用未改善模型拟合。
要点
- 基于HRS与Medicare关联数据,在多病加权指数中检验二向和三向疾病交互作用。
- 前10位疾病二向交互作用使R²从0.26升至0.27,改善幅度很小。
- 三向交互作用及扩展至前20位疾病未见模型拟合改善。
核心结论
- 纳入前10位最常见且影响最大疾病的二向交互作用仅带来极小的模型拟合改善,更精确的多病指数可同时纳入疾病主效应与显著交互作用。
研究设计与样本
- 研究纳入健康与退休研究(HRS)中关联Medicare数据的参与者,使用1991—2012年ICD-9-CM索赔数据,共分析18 212名参与者的73 830条观测,训练集N=14 570、测试集N=3 642。
- 以与躯体功能下降的关联确定前20位最常见且影响最大的疾病,采用LASSO与bootstrapping识别并保留有统计学意义的二向和三向疾病交互作用。
- 在线性模型中比较含与不含疾病交互作用的多病加权指数的模型拟合。
主要发现
- 不含交互作用的多病加权指数总体R²=0.26。
- 纳入前10位最常见且影响最大疾病的二向交互作用后R²=0.27。
- 二向交互作用扩展至前20位疾病时R²=0.26。
- 加入三向交互作用时,前10位疾病R²=0.26,扩展至前20位疾病R²=0.24。
临床怎么用
- 现有多病加权指数的加性求和已能解释大部分结局变异,常规叠加高阶交互项的边际获益有限。
- 若构建更精确的多病指数,可同时考虑疾病主效应与经统计学筛选的显著交互作用。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current multimorbidity measures often oversimplify complex disease interactions by assuming a merely additive impact of diseases on health outcomes. This oversimplification neglects clinical observations that certain disease combinations can exhibit synergistic effects. Thus, we aimed to incorporate simultaneous higher-order disease interactions into the validated ICD-coded multimorbidity-weighted index, to assess for model improvement. METHODS: Health and Retirement Study participants with linked Medicare data contributed ICD-9-CM claims, 1991-2012. Top 20 most prevalent and impactful conditions (based on associations with decline in physical functioning) were assessed through higher-order interactions (2-way, 3-way). We applied the least absolute shrinkage and selection operator and bootstrapping to identify and retain statistically significant disease interactions. We compared model fit in multimorbidity-weighted index with and without disease interactions in linear models. RESULTS: We analyzed 73 830 observations from 18 212 participants (training set N = 14 570, testing set N = 3 642). Multimorbidity-weighted index without interactions produced an overall R2 = 0.26. Introducing 2-way interactions for the top 10 most prevalent and impactful conditions resulted in a R2 = 0.27, while expanding to top 20 most prevalent and impactful conditions yielded a R2 = 0.26. When adding 3-way interactions, the same top 10 conditions produced a R2 = 0.26, while expanding to top 20 conditions resulted in a R2 = 0.24. CONCLUSIONS: We present novel insights into simultaneous higher-order disease interactions for potential integration into multimorbidity measurement. Incorporating 2-way disease interactions for the top 10 most prevalent and impactful conditions showed a minimal improvement in model fit. A more precise multimorbidity index may incorporate both the main effects of diseases and their significant interactions.
引用
- Wei MY, Tseng CH, Kang AJ, et al. Higher-Order Disease Interactions in Multimorbidity Measurement: Marginal Benefit Over Additive Disease Summation. J Gerontol A Biol Sci Med Sci. 2024. PMID: 39565288. doi:10.1093/gerona/glae282
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。